U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07937254) titled 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)' on Nov. 08.
Brief Summary: This first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and effects on Lp(a) of single ascending doses of JAR-2203 in healthy adults with elevated Lp(a).
Study Start Date: Oct. 19
Study Type: INTERVENTIONAL
Condition:
Lipid Metabolism Disorders
Healthy Volunteers - Male and Female
Hyperlipoproteinemia(a)
Intervention:
DRUG: JAR-2203
JAR-2203 solution for injection given as a single subcutaneous injection; planned dose levels ar...